(S)-(2- (6-Chloro-7-methyl-1H-benzo [D] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2 as an orexin receptor antagonist -(2H-1,2,3-triazol-2-yl) phenyl) methanone salt crystal form
The present invention relates to (S)-(2- (6-chloro-7-methyl-1H-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- ( 2H-1,2,3-triazol-2-yl) phenyl) methanone hydrochloride crystalline form, process for its preparation, pharmaceutical composition comprising said crystalline form, and its use as a medicament, in particular as an orexin receptor antagonist About. [Selection] Figure 2本発明は、(S)-(2-(6-クロロ-7-メチル-1H-ベンゾ[d]イミダゾール-2-イル)-2-メチルピロリジン-1-イル)(5-メトキシ-2-(2H-1,2,3-トリアゾール-2-イル)フェニル)メタノン塩酸塩の結晶形、その製造方法、当該結晶形を含む医薬組成物、及び医薬としての、特にオレキシン受容体アンタゴニストとしてのその使用に関する。【選択図】 図2